Jonas Hugosson1, Rebecka Arnsrud Godtman1, Sigrid V Carlsson1,2,3, Gunnar Aus4, Anna Grenabo Bergdahl1, Pär Lodding1, Carl-Gustaf Pihl5, Johan Stranne1, Erik Holmberg6, Hans Lilja2,7,8,9,10. 1. a Department of Urology, Institute of Clinical Sciences , Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital , Gothenburg , Sweden. 2. b Department of Surgery (Urology Service) , Memorial Sloan Kettering Cancer Center , New York , NY , USA. 3. c Department of Epidemiology and Biostatistics , Memorial Sloan Kettering Cancer Center , New York , NY , USA. 4. d Department of Urology , Carlanderska Hospital , Gothenburg , Sweden. 5. e Department of Pathology, Institute of Biomedicine , Sahlgrenska Academy at University of Gothenburg , Gothenburg , Sweden. 6. f Department of Oncology, Institute of Clinical Sciences , Sahlgrenska Academy at University of Gothenburg , Gothenburg , Sweden. 7. g Department of Laboratory Medicine , Memorial Sloan Kettering Cancer Center , New York , NY , USA. 8. h Department of Medicine (Genitourinary Oncology Service) , Memorial Sloan Kettering Cancer Center , New York , NY , USA. 9. i Nuffield Department of Surgical Sciences , University of Oxford , Oxford , UK. 10. j Department of Translational Medicine , Lund University, Skåne University Hospital , Malmö , Sweden.
Abstract
OBJECTIVE: This study examined whether previously reported results, indicating that prostate-specific antigen (PSA) screening can reduce prostate cancer (PC) mortality regardless of sociodemographic inequality, could be corroborated in an 18 year follow-up. MATERIALS AND METHODS:In 1994, 20,000 men aged 50-64 years were randomized from the Göteborg population register to PSA screening or control (1:1) (study ID: ISRCTN54449243). Men in the screening group (n = 9950) were invited for biennial PSA testing up to the median age of 69 years. Prostate biopsy was recommended for men with PSA ≥2.5 ng/ml. Last follow-up was on 31 December 2012. RESULTS: In the screening group, 77% (7647/9950) attended at least once. After 18 years, 1396 men in the screening group and 962 controls had been diagnosed with PC [hazard ratio 1.51, 95% confidence interval (CI) 1.39-1.64]. Cumulative PC mortality was 0.98% (95% CI 0.78-1.22%) in the screening group versus 1.50% (95% CI 1.26-1.79%) in controls, an absolute reduction of 0.52% (95% CI 0.17-0.87%). The rate ratio (RR) for PC death was 0.65 (95% CI 0.49-0.87). To prevent one death from PC, the number needed to invite was 231 and the number needed to diagnose was 10. Systematic PSA screening demonstrated greater benefit in PC mortality for men who started screening at age 55-59 years (RR 0.47, 95% CI 0.29-0.78) and men with low education (RR 0.49, 95% CI 0.31-0.78). CONCLUSIONS: These data corroborate previous findings that systematic PSA screening reduces PC mortality and suggest that systematic screening may reduce sociodemographic inequality in PC mortality.
RCT Entities:
OBJECTIVE: This study examined whether previously reported results, indicating that prostate-specific antigen (PSA) screening can reduce prostate cancer (PC) mortality regardless of sociodemographic inequality, could be corroborated in an 18 year follow-up. MATERIALS AND METHODS: In 1994, 20,000 men aged 50-64 years were randomized from the Göteborg population register to PSA screening or control (1:1) (study ID: ISRCTN54449243). Men in the screening group (n = 9950) were invited for biennial PSA testing up to the median age of 69 years. Prostate biopsy was recommended for men with PSA ≥2.5 ng/ml. Last follow-up was on 31 December 2012. RESULTS: In the screening group, 77% (7647/9950) attended at least once. After 18 years, 1396 men in the screening group and 962 controls had been diagnosed with PC [hazard ratio 1.51, 95% confidence interval (CI) 1.39-1.64]. Cumulative PC mortality was 0.98% (95% CI 0.78-1.22%) in the screening group versus 1.50% (95% CI 1.26-1.79%) in controls, an absolute reduction of 0.52% (95% CI 0.17-0.87%). The rate ratio (RR) for PC death was 0.65 (95% CI 0.49-0.87). To prevent one death from PC, the number needed to invite was 231 and the number needed to diagnose was 10. Systematic PSA screening demonstrated greater benefit in PC mortality for men who started screening at age 55-59 years (RR 0.47, 95% CI 0.29-0.78) and men with low education (RR 0.49, 95% CI 0.31-0.78). CONCLUSIONS: These data corroborate previous findings that systematic PSA screening reduces PC mortality and suggest that systematic screening may reduce sociodemographic inequality in PC mortality.
Entities:
Keywords:
Mass screening; prostate cancer; prostate-specific antigen; socioeconomic factors
Authors: Sigrid Carlsson; Melissa Assel; David Ulmert; Axel Gerdtsson; Jonas Hugosson; Andrew Vickers; Hans Lilja Journal: Eur Urol Date: 2016-04-13 Impact factor: 20.096
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen Journal: N Engl J Med Date: 2012-03-15 Impact factor: 91.245
Authors: Tuomas P Kilpeläinen; Teuvo L Tammela; Nea Malila; Matti Hakama; Henrikki Santti; Liisa Määttänen; Ulf-Håkan Stenman; Paula Kujala; Anssi Auvinen Journal: J Natl Cancer Inst Date: 2013-03-11 Impact factor: 13.506
Authors: Elisabetta Rapiti; Gerald Fioretta; Robin Schaffar; Isabel Neyroud-Caspar; Helena M Verkooijen; Franz Schmidlin; Raymond Miralbell; Roberto Zanetti; Christine Bouchardy Journal: Cancer Date: 2009-12-01 Impact factor: 6.860
Authors: Monique J Roobol; Ries Kranse; Chris H Bangma; Arno G J L H van Leenders; Bert G Blijenberg; Ron H N van Schaik; Wim J Kirkels; Suzie J Otto; Theo H van der Kwast; Harry J de Koning; Fritz H Schröder Journal: Eur Urol Date: 2013-05-25 Impact factor: 20.096
Authors: Maria Frånlund; Marianne Månsson; Rebecka Arnsrud Godtman; Gunnar Aus; Erik Holmberg; Karin Stinesen Kollberg; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Hans Lilja; Jonas Hugosson Journal: J Urol Date: 2022-04-15 Impact factor: 7.600
Authors: Elizabeth C Page; Elizabeth K Bancroft; Mark N Brook; Melissa Assel; Mona Hassan Al Battat; Sarah Thomas; Natalie Taylor; Anthony Chamberlain; Jennifer Pope; Holly Ni Raghallaigh; D Gareth Evans; Jeanette Rothwell; Lovise Maehle; Eli Marie Grindedal; Paul James; Lyon Mascarenhas; Joanne McKinley; Lucy Side; Tessy Thomas; Christi van Asperen; Hans Vasen; Lambertus A Kiemeney; Janneke Ringelberg; Thomas Dyrsø Jensen; Palle J S Osther; Brian T Helfand; Elena Genova; Rogier A Oldenburg; Cezary Cybulski; Dominika Wokolorczyk; Kai-Ren Ong; Camilla Huber; Jimmy Lam; Louise Taylor; Monica Salinas; Lidia Feliubadaló; Jan C Oosterwijk; Wendy van Zelst-Stams; Jackie Cook; Derek J Rosario; Susan Domchek; Jacquelyn Powers; Saundra Buys; Karen O'Toole; Margreet G E M Ausems; Rita K Schmutzler; Kerstin Rhiem; Louise Izatt; Vishakha Tripathi; Manuel R Teixeira; Marta Cardoso; William D Foulkes; Armen Aprikian; Heleen van Randeraad; Rosemarie Davidson; Mark Longmuir; Mariëlle W G Ruijs; Apollonia T J M Helderman van den Enden; Muriel Adank; Rachel Williams; Lesley Andrews; Declan G Murphy; Dorothy Halliday; Lisa Walker; Annelie Liljegren; Stefan Carlsson; Ashraf Azzabi; Irene Jobson; Catherine Morton; Kylie Shackleton; Katie Snape; Helen Hanson; Marion Harris; Marc Tischkowitz; Amy Taylor; Judy Kirk; Rachel Susman; Rakefet Chen-Shtoyerman; Allan Spigelman; Nicholas Pachter; Munaza Ahmed; Teresa Ramon Y Cajal; Janez Zgajnar; Carole Brewer; Neus Gadea; Angela F Brady; Theo van Os; David Gallagher; Oskar Johannsson; Alan Donaldson; Julian Barwell; Nicola Nicolai; Eitan Friedman; Elias Obeid; Lynn Greenhalgh; Vedang Murthy; Lucia Copakova; Sibel Saya; John McGrath; Peter Cooke; Karina Rønlund; Kate Richardson; Alex Henderson; Soo H Teo; Banu Arun; Karin Kast; Alexander Dias; Neil K Aaronson; Audrey Ardern-Jones; Chris H Bangma; Elena Castro; David Dearnaley; Diana M Eccles; Karen Tricker; Jorunn Eyfjord; Alison Falconer; Christopher Foster; Henrik Gronberg; Freddie C Hamdy; Vigdis Stefansdottir; Vincent Khoo; Geoffrey J Lindeman; Jan Lubinski; Karol Axcrona; Christos Mikropoulos; Anita Mitra; Clare Moynihan; Gadi Rennert; Mohnish Suri; Penny Wilson; Tim Dudderidge; Judith Offman; Zsofia Kote-Jarai; Andrew Vickers; Hans Lilja; Rosalind A Eeles Journal: Eur Urol Date: 2019-09-16 Impact factor: 20.096
Authors: Evan Kovac; Sigrid V Carlsson; Hans Lilja; Jonas Hugosson; Michael W Kattan; Erik Holmberg; Andrew J Stephenson Journal: JAMA Netw Open Date: 2020-01-03